Carcinoma Breast Stage IV
Conditions
Keywords
SAID, Progestogens, nSAID-resistanced, LSBC
Brief summary
Steroid Aromatase Inhibitors and Non-Steroid Aromatase Inhibitors in Late Stage Breast Cancer is the recommended scheme in National Comprehensive Cancer Network (NCCN) guideline. In the past controlled clinical trials with small sample.
Detailed description
A Randomized Study of Steroid Aromatase Inhibitors Versus Progestogens for Non-Steroid Aromatase Inhibitor-resistanced Late Stage Breast Cancer.The primary endpoints of the study is progression free survival (PFS). The secondary endpoints are overall response rate (ORR), overall survival (OS) and safety.
Interventions
None listed
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
1. Patients must be the postmenopausal women 2. Patients must be diagnosed with advanced breast cancer by imageology，cytology or histopathology 3. Immunohistochemistry shows ER and/or PR positive 4. Patients ECOG score must be 0-2 5. Drug resistant about Non-Steroid Aromatase Inhibitors
Exclusion criteria
1. Not suitable for endocrine therapy 2. Have receive the standard Steroid Aromatase Inhibitors treatment 3. Severe hepatic dysfunction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RECIST 1.1 | -7 days |
Countries
China
Contacts
Primary ContactYehui Shi, MD
Outcome results
None listed